Compare Medpace Holdings Inc (MEDP) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Nutrien Ltd — how do they compare? Medpace Holdings Inc trades at $618.69 (market cap $16.82B), while Nutrien Ltd trades at $67.79 (market cap $33.31B). The key difference: Nutrien Ltd is the larger of the two by market cap, and Nutrien Ltd pays a 3.15% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Nutrien Ltd for 59 Days on average.
| MEDP | NTR | |
|---|---|---|
Market Cap | $16.82B | $33.31B |
Volume | 223,093 | 1,330,729 |
Sector | Health | Basic Materials |
52-Week High | $630.19 | $83.94 |
52-Week Low | $393.42 | $53.64 |
Typical Hold Time | 14 Days | 59 Days |
Enterprise Value | $16.44B | $45.11B |
Dividend Yield | — | 3.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Nutrien (NTR) trades at $68.29, down 2.4% today, with a bearish technical signal and mixed earnings history. The stock shows moderate valuation metrics with P/E of 14.14 and P/S of 1.2, while profitability metrics include 8.44% net margin and 9.34% ROE. Recent news highlights industry headwinds from potential Belarus potash imports and an upcoming Investor Day in November 2026.
The outlook remains cautiously optimistic with 60.6% analyst buy ratings and a $76.14 consensus target, though risks include fertilizer price volatility and competitive pressures. Cash flow trends show consistent operational strength but negative net flows in recent years, requiring careful monitoring of debt levels and agricultural market cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
